Calixar and Synthelis team up to provide unique membrane protein services

09-Jul-2012 - France

Calixar and Synthelis announced that they have entered into an alliance for the production and isolation of all types of target membrane proteins. The results of this collaboration will have applications ranging from the development of antibodies to the discovery of new drugs, including the determination of the structure of these targets and vaccine formulations.
 
Instead of trying to produce these proteins themselves, users will be given access to state-of-the-art production and purification technologies, enabling them to concentrate on their core activities. Furthermore, thanks to the critical mass of skills and technologies made available to them, they will be assured of obtaining targets in their native conformation, thus guaranteeing the success of their programs for developing new drugs, vaccines and therapeutic antibodies.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous